Searched for
DRUG FIRM CIPLA
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Cipla to tap foreign cos for large-scale vax playMoving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now...
- Collaborating with government agencies to develop treatment for COVID-19: CiplaBesides scaling up production of medicines that show potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromyci...
- Cipla witnesses 3 senior-level exits including India biz CEODrug firm Cipla has witnessed three senior-level exits, including that of the company's Executive Vice-President and CEO for India business...
- Cipla jumps 8% on completing Phase-3 clinical study of asthma drugThe generic would be used for treatment of asthma and chronic obstructive pulmonary disease.
- USFDA issues warning letter to Cipla for Goa manufacturing facilityDrug firm Cipla Ltd said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa. The...
- Cipla shares rise after Vysov anti-diabetic drug acquisitionCipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the ...
- Cipla meets Street expectations, posts 19% YoY rise in Q2 profitTotal income from operation increased 8.83 per cent YoY to Rs 4,082.41 crore in Q2
- Cipla gets USFDA nod for Hepatitis B treatment drugThe tablets are generic versions of Bristol-Myers Suibb's Baraclude tablets of the same strength, Cipla said.
- Cipla to invest Rs 590 crore for a biosimilars plant in South AfricaDrug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the producti...
- Cipla invests additional $ 3 million in US's Chase PharmaceuticalsDrug firm Cipla Ltd has made an additional investment of USD 3 million in US-based Chase Pharmaceuticals engaged in developing novel approa...
- Cipla to launch generic Hepatitis C drug 'Hepcvir' in IndiaThe availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.
- Delhi High Court notice to Novartis on Cipla plea"We will not give you an interim order. We will hear it on an early date and dispose it of. Notice. Renotify on February 5," the bench said.
- Cipla to pick 14.6% stake in Chase Pharmaceuticals for $1.5 mnCipla also said it will make an additional USD 4.5 million investment in Chase upon achievement of certain milestones.
- Cipla's anti-malaria drug receives WHO pre-qualificationCipla today said an anti-malarial drug developed by Drugs for Neglected Diseases initiative (DNDi) has received pre-qualification from WHO.
- Cipla's clone of Bayer cancer drug gets nodThis case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
- Cipla receives notices from NPPA for alleged overchargingDrug firm Cipla said it has received notices from the drug price regulator National Pharmaceutical Pricing Authority allegedly for over-pri...
- SC asks Chennai patent office to hear RocheThe SC asked the Chennai patent office to hear and take a final view for all post-grant oppositions for a patent it had granted to Swiss co...
Load More
